~~<i id='95EA6E912C'><strike id='95EA6E912C'><tt id='95EA6E912C'><pre id='95EA6E912C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：Wikipedia 2025-09-14 21:42:31 - browse：41

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： 5 takeaways from STAT's examination of Zynex Medical

hotspot

knowledge

focus

hotspot

explore

Wikipedia

AdobeWhenoursonPeterwasdiagnosedwithanultra-rareformofmusculardystrophyattheageof10,thefirstquestion

WSS

A new approach to psychiatric drug development

5 takeaways from STAT's examination of Zynex Medical

The public health thinking behind the CDC’s new Covid guidance

Microsoft's Peter Lee: Generative AI could help doctors be more human

Pharma companies must ensure equitable access to obesity drugs

A new approach to psychiatric drug development

hotspot

leisure time

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Novavax promises a turnaround & Lilly roils the obesity market

First over

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pharma companies must ensure equitable access to obesity drugs

Wildfire smoke exposes gaps in outdoor worker protections

Cigna wins case to block Amy Bricker's move to CVS

In age of alternative facts, a scholarly course on calling out crap

Stem cell biologist probes earliest stages of human development

knowledge

State of the Union pitch: Bigger Medicare drug price negotiations

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Streamlined flu vaccines recommended by FDA advisory panel

Coercive sterilizations revealed by STAT prompt outrage

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

focus

hotspot

explore

Wikipedia